Skip to main content
. Author manuscript; available in PMC: 2015 Jan 18.
Published in final edited form as: Nat Commun. 2014 Jul 18;5:4387. doi: 10.1038/ncomms5387

Figure 7.

Figure 7

Intra-tracheal application of rhMG53 protects LPS-induced lung remodeling in mice. Animals were first treated with LPS (i.t., 3 times per week, for 5 weeks) followed by MBP-MG53 or MBP-MBP in control group (i.t., 5 days/week for 5 weeks). Lungs were collected 5 weeks after initial LPS application for evaluation. A. MBP-MG53 prevents emphysema in LPS-induced chronic lung remodeling. B. Histology H/E staining of parenchyma in LPS-induced emphysematous lung (Scale bars are equal to 100 μm). C. Statistical results for EELV, lung elastance and Lm in LPS-induced emphysematous lung treated with different doses of rMG53 (mg/kg, 0.1, 0.3, 1.0) and 1 mg/kg control protein, n=7-10, *P<0.05 compared to no LPS control group (open bar) and #P<0.05 compared with saline-treated, LPS-challenged group. n=7-10 (Mann-Whitney U analysis).